Abbisko set for milestone payout after first U.S. drug approval

The Chinese drug developer stands to receive $20 million plus royalties under a Merck licensing deal after its treatment for a joint disorder was cleared for U.S. sale
Key Takeaways:
- In the first half, around 96% of Abbisko revenue came from the Merck licensing agreement and the company still landed in the red
- The company has signed collaboration deals for other experimental drugs with Eli Lilly and AstraZeneca
By Molly Wen
Getting the green light from U.S. regulators to launch an innovative medicine onto the market is a major milestone for a drug developer, serving to endorse its R&D expertise.
China’s Abbisko Medicine Co. Ltd. (2256.HK) is celebrating just such a landmark after the U.S. Food and Drug Administration (FDA) approved sales of the firm’s self-developed oral drug to treat a condition affecting joints and tendons.
The regulatory clearance for pimicotinib, announced on Nov. 11, puts the Chinese drugmaker in line to receive a $20 million milestone payment under a licensing agreement with the German pharmaceutical giant Merck as well as royalties on sales in the United States, the world’s biggest market for innovative medicines.
The suppressant drug was approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), in which non-cancerous growths cause swelling and stiffness. Abbisko independently discovered the drug and advanced it through a global Phase Three trial. The drug had previously won approval in China, Canada and Switzerland.
Abbisko’s share of the U.S. proceeds is governed by the terms of a 2023 deal in which Merck paid $70 million upfront for exclusive commercialization rights to pimicotinib in mainland China, Hong Kong, Macao and Taiwan. Last year Merck paid a further $85 million to exercise an exclusive option to expand those rights worldwide.
The potential value of the entire deal including upfront, option and milestone payments came to around $605.5 million, with double-digit royalties on global net sales on top of that figure.
Spurred by the prospect of a $20 million milestone payout, Abbisko’s shares rose 5.2% to close at HK$6.655 on the day the U.S. approval was announced. They advanced another 8.2% to HK$7.20 in the following session, bringing the two-day gain to around 14%. Meanwhile, founder and CEO Xu Yao-Chang bought 145,000 shares on the open market on Nov. 11 at an average price of HK$6.67, spending about HK$967,000 ($123,250) and taking his stake to about 11.26% of the company’s issued shares.
TGCT can cause pain, swelling and restricted movement around the joints and tendons, although the growths are typically benign. Pimicotinib, an oral small-molecule drug, inhibits the signaling protein behind the condition, known as colony-stimulating factor 1 receptor (CSF-1R). The Abbisko drug enters the U.S. market in direct competition with Daiichi Sankyo’s Turalio and Deciphera’s Romvimza, which have already been approved.
The Chinese market generated Abbisko’s first royalty income for pimicotinib, but licensing payments still make up most of the revenue from the drug. In the first half of 2026, pimicotinib licensing revenue amounted to 93.18 million yuan ($14 million), around 96% of total revenue, which fell 84% year on year to 97.27 million yuan. The first prescription in the Chinese mainland in March triggered approximately 92 million yuan in milestone revenue, while royalties recognized during the first half totaled about 1.1 million yuan.
Next drugs in the pipeline
In the same period of 2025, Merck’s $85 million option payment helped lift Abbisko’s revenue to 612 million yuan for a profit of 328 million yuan. Without a comparable first-half boost this year, and with R&D spending rising 8% to 246 million yuan, the company swung to a loss of 193 million yuan, using around 221 million of net cash in operating activities. By mid-year, cash and bank balances had risen about 17% from the end of 2025 to nearly 2.38 billion yuan, supported by a share placement and licensing income from strategic partnerships.
Beyond pimicotinib, a collaboration with Eli Lilly offers another promising source of growth. In June, the companies agreed a deal under which Abbisko will conduct drug discovery and early development for targets selected by Lilly. Upfront and potential milestone payments amount to around $1.9 billion, with royalties payable separately. In July, Abbisko announced it was collaborating with AstraZeneca on a clinical study combining its oral PD-L1 inhibitor ABSK043 with the lung cancer drug osimertinib, without disclosing licensing or payment terms.
A potential liver cancer treatment developed by Abbisko, irpagratinib (ABSK011), is among the company’s more advanced candidate drugs. The treatment has entered a registrational study in China for previously treated patients whose tumors overexpress FGF19, and dosing has also begun in the United States in a global Phase Two study. Another small-molecule drug, ABSK061, targets the bone growth disorder achondroplasia in children, with preliminary Phase Two data announced in September.
Abbisko’s market value is less than HK$5 billion, and its price-to-sales ratio stands at around 40, above the roughly 34 times for Duality Biotherapeutics (9606.HK), another innovative drugmaker that relies mainly on licensing revenue. Looking beyond the latest milestone payment, the more important question for investors is whether royalties can start to deliver stable revenue as pimicotinib enters the U.S. and other markets.
To subscribe to Bamboo Works weekly free newsletter, click here